Efficacy and safety of evacetrapib for modifying plasma lipids: A systematic review and meta-analysis of randomized controlled trials

Current Pharmaceutical Design

Volumn 22, Issue 5, 2016, Pages 595-608

  Sahebkar, Amirhossein ^a,b   Simental Mendía, Luis E ^c   Guerrero Romero, Fernando ^c   Golledge, Jonathan ^d,e   Watts, Gerald F ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d JAMES COOK UNIVERSITY   (Australia)

^e TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Cholesteryl ester transfer protein inhibitor; Evacetrapib; High density lipoprotein cholesterol; Lipids; Low density lipoprotein cholesterol; Meta analysis; Triglycerides

Indexed keywords

EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE ENZYME; PLACEBO; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELEVATED BLOOD PRESSURE; HUMAN; LIPID BLOOD LEVEL; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; SAFETY;

ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY;

EID: 84958241083     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151125000035     Document Type: Article

References (38)

1. Colin S, Chinetti-Gbaguidi G, Kuivenhoven JA, Staels B. Emerging small molecule drugs. Handb Exp Pharmacol 2015; 224: 617-30.
2. Nicholls SJ. Evacetrapib. Curr Cardiol Rep 2012; 14(3): 245-50.
3. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014; 15(4): 493-503.
4. Sahebkar A, Watts GF. Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies. Clin Lipid 2014; 9(2): 221-233.
5. Sahebkar A, Chew GT, Watts GF. Recent advances in pharma-cotherapy for hypertriglyceridemia. Prog Lipid Res 2014; 56C: 47-66.
6. Sahebkar, A, Watts GF. Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes Obes Metab 2014; 16: 780-792.
7. Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 2013; 27(6): 559-67.
8. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syn- dromes. Clin Ther 2013; 35(8): 1082-98.
9. Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2(1): 26-33.
10. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299(23): 2777-88.
11. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380(9841): 572-80.
12. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004; 45(5): 948-53.
13. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357(21): 2109-22.
14. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-99.
15. Lüscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33(7): 857-65.
16. Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363(25): 2406-15.
17. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combina- tion with statins on HDL and LDL cholesterol: a randomized con- trolled trial. JAMA 2011; 306 (19): 2099-109.
18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
19. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. London: The Cochrane Collboration; 2009.
20. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 2. Englewood, NJ: Biostat 2005.
21. Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015; 60: 50-73.
22. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014; 28(5): 633-42.
23. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta analysis. Biometrics 2000; 56(2): 455-63.
24. Suico JG, Wang MD, Friedrich S, et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipo proteins and 24-h ambulatory blood pressure in healthy adults. J Pharm Pharmacol 2014; 66(11): 1576-85.
25. Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, Krueger KA. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Am J Cardiol 2014; 113(12): 2021-9.
26. Li C, Zhang W, Zhou F, et al. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. PLoS One 2013; 8(10): e77049.
27. Grigore L, Norata GD, Catapano AL. Combination therapy in cho-lesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008; 4(2): 267-78.
28. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 2012; 33(12): 1451-8.
29. Kühnast S, van der Tuin SJ, van der Hoorn JW, et al. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non- HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J 2015; 36(1): 39-50.
30. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardio-vascular disease in the community. Circulation 2009; 120(24): 2414-20.
31. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23(2): 160-7.
32. Ritsch A, Scharnagl H, Eller P, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010; 121(3): 366-74.
33. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009; 150(5): 2211-9.
34. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors down-regulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis 2014; 235(2): 449-62.
35. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism 2014; 63(12): 1469-79.
36. Martinez LRC, Santos RD, Miname MH, Deus DF, Lima ES, Maranhão RC. Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia. Metabolism 2013; 62(8): 1061-4.
37. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabolism 2013; 62(4): 479-91.
38. Aronis KN, Mantzoros CS. Novel concepts in lipoprotein particle metabolism and regulation. Metabolism 2014; 63(1): 4.